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Liposomes containing monosialoganglioside (G,,) or polyethylene glycol (PEG) lipid derivatives have prolonged circulation in the blood. This 
favours liposome extravasation to tumour sites. In this report it is shown that inclusion of G,,, PEGS,-DPPB or PEGmxrDPPE in liposomes 
containing biotin-DPPE signiticantly diminished the ability of vesicles to bind to streptavidin in vitro. Steric inhibition due to the bulky head group 
of these lipids was least for biotin-DPPE liposomes contaming C&i. Bi~st~bu~on studies in CZ6 t~o~-~a~ng mice showed that ~~~-~~sornes 
containing small amo~ts of biotin-DPPE have long circulation l&-times in the blood. Using fluorescent microscopic techniques, liposomes 
contaming both G,, and biot~-DPPE were detected within ex~-vault spaces in tumours. In addition it was shown that biotin-DPPE in 
G&iposomes bound streptavidin in situ. These results suggest hat G,,-liposomes containing biotin-DPPE have potential use as diagnostic or 
therapeutic reagents in pre-targeting applications dependent on the high-a&&y interaction of biotiu with streptavidin. 
LipOSOme; Streptavidin; Biotin; Ganglioside; Polyethyle~~yco~ Targeted liposome 
1. INTRODUCTION 
Significant progress has been achieved in the develop- 
ment of liposomes as carriers of therapeutic or diagnos- 
tic agents [1,2]. The first liposome formulations were 
designed such that uptake by the retic~oendothe~al 
system was minimised f3]. These liposomes circulate for 
extended times and as a consequence xtravasate and 
reach tumour sites [4]. This property (also referred to 
as ‘stealth’; LTI, Menlo Park, CA) is achieved by incor- 
poration of lipids such as G,, or PEG derivatives of 
phosphatidylethanolamine in liposome preparations. It 
has been suggested that sterically stabilised liposome 
formulations which have the ability to bind to target 
ligands in situ have potential applications for drug tar- 
geting to tumour tissues [q. 
Tumour-specific targeting of liposomes can be 
achieved in vivo in two ways. A targeting molecule may 
be attached directly to liposomes by non-covalent [6] or 
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covalent strategies [7-10) prior to administration. Alter- 
natively tumours may be labelled in vivo indirectly by 
exploiting ~~-a~ity interactions based on reagents 
such as biotin and s~pta~~n. In this case, Iabelling of 
selected tissues may be achieved in three steps by admin- 
istration of biotinylated antibody, a bridging moleoule, 
such as avidin or strep~~~, and lastly biotinylated 
liposomes. In A recent study, a step-wise approach to 
targeting was used successfully to localise ““In-labelled 
biotin to tumours El 11. Substitution of radioactively la- 
belled biotin with biotin-derivatised vesicles containing 
large amounts of radioactive nuclides (or anti-cancer 
drugs) may further aid in early detection and treatment 
of cancer. 
The ability to target bio~ylated liposomes to tu- 
mour sites in vivo will depend on a number of factors. 
Access of liposomes to avidin- or streptavidin-coated 
cells within the tumour is a pre-requisite. Secondly bio- 
tin lipid derivatives must remain stabily associated with 
liposomes in vivo. In addition, lipid components incor- 
porated into liposome systems should not hinder the 
high-af&ity binding of streptavidin to biotin-liposomes 
in vivo. In this report we first describe studies aimed at 
optimising the binding of streptavidin to biotinylated- 
liposomes in vitro. We then describe the in vivo behav- 
iour of liposomes containing biotin lipid derivatives in 
turnour-big mice. This isolation should aid in 
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the development of liposome based pre-targeting proto- 
cols for drug targeting applications. 
2. MATERIALS AND METHODS 
2.1. Materials 
Egg phosphatidylcholine (EPC) was obtained from Avanti Polar 
Lipids (Alabaster, USA). N-((monomethoxy-polyethyleneglyco&,& 
succinoyl)-2-oleoyl-l-palmitoyl-sn-glycero-3-phospho-ethanol~ne 
(MePEG,S-POPE) and N-((monomethoxy-polyethyleneglycol,,,) 
succinoyl)-2-oleoyl-l-palmitoyl-sn-glycero-3-phospho-ethanola~ne 
(MePEG,,-S-POPE) were gifts from Lipex Lipids Inc. (Vancouver, 
Canada). N-Biotinoyl dipahnitoyl phosphatidylethanolamine (biotin- 
DPPE), cholesteryl4,4-ditluoro-5,7dithyl4bora-3a,4a-diaza-~-in- 
dacene-3-dodecanoate (cholesteryl-BODIPY FL C12) and rhodamine 
123 were purchased from Molecular Probes (Eugene, USA). Monosia- 
loganglioside (G,,) was a gift from Fidia (Abano Terme, Italy). 
Cholesterol, Texas red-labelled streptavidin, Tween 20, A23187, di- 
ethylene-tetraamino pentaacetic acid (DTPA), HEPES and citric acid 
were purchased rom Sigma Chemical Co. All other chemicals were of 
standard grade. Balb/c female mice (18-20 g) were obtained from 
Charles River (Calco, Italy). C-26 colon carcinoma cells were kindly 
supplied by Dr. G. Parmiani of the Istituto Nazionale Tumori in 
Milano. 
2.2. Preparation of liposomes 
Large unilamellar vesicles (LUVs) were prepared as described by 
Hope et al. [12]. Briefly, appropriate amounts of lipid mixtures dis- 
solved in chloroform were deposited in a tube and dried to a lipid film 
under a stream of nitrogen followed by high vacuum for 2 h. Lipid 
samples were hydrated in the appropriate buffer, frozen and thawed 
5 times and extruded 10 times through two stacked 100 nm polycar- 
bonate filters. Liposome size, as estimated by Quasi-elastic light scat- 
tering (Brookhaven, Holtsville, USA) for all liposome preparations 
studied was between 9&l 15 nm. 
2.3. Remote loading of liposomes with aqueous markers 
Rhodamine 123-loaded liposomes (EPC 59.9-59 mol%; cholesterol 
40 mol%) containing biotin-DPPE (0.1-l mol%) were prepared by a 
modification of the procedure of Mayer et al. [13,14]. For sterically 
stabilised liposome samples Gu,, PEGSM or PEG, (5 mol%) were 
included in the lipid film. In brief, liposomes prepared in 300 mM citric 
acid buffer, pH 4.0, were exchanged on PD-10 columns (Pharmacia) 
equilibrated with 25 mM EPPS, 150 mM NaCl, pH 8.5. Rhodamine 
123 (100 nmol) was incubated with chromatographed liposomes (5 
mM total lipid) for 15 min at 6O’C. Unencapsulated rhodamine 123 
was separated from liposomes by gel filtration on PD-10 columns 
equilibrated with 25 mM HEPES, 150 mM NaCl, pH 7.5 (HBS). 
Rhodamine 123 was estimated by monitoring fluorescence at 536 nm 
using a Perkin Elmer L5 spectrofluorimeter with an excitation wave- 
length of 512 nm. Phospholipid was determined by the calorimetric 
method of Fiske and Subbarrow [15]. 
“‘In-loaded vesicles were prepared by the method of Mauk and 
Gamble [16]. Briefly, liposomes composed of EPC (w35.25 pmol), 
cholesterol (20 pmol), GM, (4 pmol), biotin-DPPE (0.16-3.2 pmol) 
and the ionophore, A23 187 (0.16 mol), were prepared by hydrating 
the lipid film in HBS containing the chelator DTPA (10 mM). Li- 
posomes were incubated with “‘InCl, (30-40 PCi) in sodium citrate 
buffer, pH 7.4, after removal of unentrapped DTPA by column 
chromatography on Sephadex G-25 equilibrated with HBS. The molar 
ratio of DTPA to InCl, was 5:0.15 and the log [citratel&Clr] was 2.5 
in the incubation mixture. After 1 h incubation at 5560°C, vesicles 
were chromatographed on PD-10 columns equilibrated with HBS to 
remove unentrapped “‘In. Aliquots were counted in a LKB gamma 
counter (Bromma, Sweden) to estimate “‘In levels. Efficiency of “‘In 
encapsulation in liposomes varied between 60-898. 
2.4. Binding of biotin-DPPE liposomes to streptavidin in vitro 
Rhodamine 123 was loaded into liposomes as described. Binding of 
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liposome preparations containing biotin-DPPE to streptavidin was 
studied on microtitre plates [14]. First, 96-well plates (Nunc) were 
coated with streptavidin by incubating protein (1 &well in 50 mM 
carbonate buffer, pH 9.6) with plates at 37°C for 1 h. Plates were then 
washed with Tween wash solution (0.05% Tween 20 in 150 mM NaCl) 
3 times and then once with HBS to remove unbound streptavidin. 
Biotin-DPPE liposomes (O-200 nmol in 200 ~1 of HBS) containing 
rhodamine 123 (80-90 nmoll~ol total lipid) were added to wells and 
plates were incubated for a further hour at 37’C. After 4 washes of 
plates with HBS, levels of plate-associated liposomes were determined 
after addition of ethanol (300~1) by estimating rhodamine 123 fluores- 
cence as described above. Non-specific binding of biotin-DPPE li- 
posomes to plates was estimated in the presence of excess free biotin 
(1,000 molar excess to the biotinylated lipid derivative in liposomes). 
2.5. Biodistribution studies in tumour-bearing mice 
Balb/c female mice were injected with C-26 colon carcinoma cells 
(l-5 x 10’). 2-3 weeks post-injection mice bearing tumours (0.7-0.8 
cm in diameter) were injected i.p. or i.v. with liposomes (EPC 62-61.25 
mol%; cholesterol 31 mol%; GH, 6.2 mol%; biotin-DPPE 0.25 mol%; 
0.5 pm01 total lipid in 0.2 ml) containing trapped “‘In (15-20 &i). 
At indicated times, blood was collected under ether anesthesia by 
cardiac puncture in heparinised tubes. For studies on the biodistribu- 
tion of liposomes, animals were sacrificed by cervical dislocation. 
Organs were removed, washed with heparinised saline, weighed, and 
levels of “‘In liposomes in tissues and blood were estimated by 
counted samples in a LKB gamma counter (Bromma, Sweden). Re- 
sults are expressed as a percentage of the injected dose normal&d per 
g of tissue [ll]. 
2.6. Fl~rescence spectroscopy experiments 
Liposomes (EPC/cholesterol/GM,, molar ratio 10:5:1) containing 
the non-exchangeable fluorescent cholesterol ester derivative, cholest- 
eryl-BODIPY FL Cl2 (0.5 mol%), with or without biotin-DPPE (0.25 
mol%), were prepared as described above. C26 tumour-bearing mice 
were injected with liposomes (1 pmol in 0.2 ml) by the tail vein. At 24 
h, mice were sacrificed, tumours were removed and fixed in 4% 
parafonnaldehyde overnight. Thin sections of about 22-25 p were 
prepared. In situ accessibility of the biotin moiety of DPPE in li- 
posomes was examined using Texas red-labelled streptavidin. Non- 
specific binding sites were blocked by pre-incubation of sections with 
PBS containing 1% BSA for 20 min. After several washes, sections 
were incubated with streptavidin labelled with Texas red (10 j&ml in 
PBS) for 30 min at room temperature. Slices were washed several times 
with PBS prior to fluorescent microscopic analysis. 
Fluorescence mission spectra of tumour sections were recorded 
under epi-illumination conditions by means of a Leitz microspectro- 
graph (Wetzlar, Germany) equipped with an optical multichannel 
analyser (Princeton Applied Research, Princeton, USA) mounted with 
an intensified silicon photodiode array detector (model 14201512). As 
the excitation source, a 100 W mercury lamp (Osram, Germany) was 
used, in combination with KG1 and BG38 anti-thermic filters. A UGl 
tllter (2 mm, 35&405 mn pass band) was used to select he excitation 
wavelengths. These wavelengths do not correspond to the excitation 
peaks of BODIPY and Texas red (479 and 490 mn, respectively). They 
were selected to obtain an appreciable fluorescence signal in order to 
analyse both fluorochromes imultaneously in stained samples. 
Fluorescent image analysis in tumour sections was performed under 
epi-illumination conditions by means of a photon-counting processor 
(Hamamatsu Photonic, Germany) equipped with a Hamamatsu 
C2400-09 ISIT camera attached to a Leitz Orthoplan fluorescence 
microscope. As the excitation source, a 100 W mercury lamp (Osram, 
Germany) combined with KG1 and BG38 anti-thermic filters was 
used. A UGl tilter (2 mm, 350-405 mn pass band) was used to select 
the excitation wavelengths. The 455 and 515 interference filters and 
the 630 cut-off filters were used to select he wavelengths correspond- 
ing to background, BODIPY and Texas red emissions, respectively. 
Fluorescence images were shown on a Sony Trinitron colour video 
monitor (Sony Corp., Tokyo, Japan), digitally stored on mass mag- 
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netic memory and printed as photographs or slides by means of a 
Freeze-frame video (Polaroid, Cambridge, MA, USA). Measurements 
were performed with I&z 25 x @IA 1,32) oil-immersion objectives. 
3. RESULTS 
3.1. In vitro studies 
Binding of biotin-DPPE liposome samples to strep- 
tavidin was studied on streptavidin-coated microtitre 
plates [ 151. Lipid was estimated from measurements of 
fluorescence due to vesicle-associated rhodamine 123. 
Results are expressed as the percentage of lipid bound 
to total lipid added, for a range of lipid concentrations 
(O-100 nmol added per well). As shown in Fig. 1, the 
% of lipid bound to plates decreased as the amount of 
EPC/cholesterol/biotin-DPPE liposomes added to wells 
was increased. This was due to saturation of strep- 
tavidin binding sites on plates with biotin-DPPE-li- 
posomes at concentrations greater than 50 mnol lipid. 
Lipid binding was dependent on incorporation of bio- 
tin-DPPE in vesicles as minimal amounts of biotin- 
DPPE liposomes bound to plates in the presence of 
excess free biotin (1,000 molar excess to the biotinylated 
lipid derivative in liposomes). This microtitre protocol 
was used to study the influence of lipid composition on 
the binding of biotinylated liposomes to streptavidin. 
The effect of varying the mol% of biotin-DPPE in 
liposomes on levels of lipid bound to streptavidin- 
coated plates was first studied. The results in Fig. 2 
show a clear correlation between amounts of lipid 
"1 l TOTAL BINDING 
LiPId added (nmol/w~ll) 
Fig. 1. Binding of biotin-DPPE liposomes to streptavidin coated mi- 
crotitre plates. Liposomes (EPC 59.75 mol%; cholesterol 40 mol%; 
biotin-DPPE 0.25 mol%) containing rhodamine 123 (90 nmol@mol 
lipid) were added to streptavidin-coated plates at various concentra- 
tions (0.50 nmol/well in 200,@. Plates were incubated for 1 h at 37T, 
washed, and lipid remaining bound was estimated as described in 
section 2. For non-specific lipid binding estimates, biotin-DPPE li- 
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Fig. 2. Effect of varying mol% of biotin-DPPE in EPClcholesterol 
liposomes. Binding of liposomes (EPC 59.9-59.75 mol%; cholesterol 
40 mol%; biotin-DPPE 0.1-l molb) to streptavidin-coated plates was 
determined as described in Fig. 1. Data are presented as specific 
binding of liposomes to plates. (Inset) Relationship between amount 
of biotin-DPPE in liposomes and % of lipid bound to plates. 
bound and the mol% of biotin-DPPE present in li- 
posomes. For example, as the mol% of biotin-DPPE in 
liposomes was increased from 0.1 to 1 mol%, the % 
levels of lipid bound to plates increased from 0.8 to 
1.7% when 50 run01 lipid was added to wells. As shown 
in the inset in Fig. 2, there was a non-linear relationship 
between the mol% of biotin-DPPE in liposomes and% 
lipid bound to plates. Levels of lipid bound to plates 
tended to reach saturation when liposomes were pre- 
pared containing 1 mol% biotin-DPPE. 
Considerable effort has been made to design li- 
posomes which have the ability to extravasate and reach 
tumour sites in vivo. The most common formulations 
require the incorporation of G,, or PEG derivatives of 
PE in the lipid membrane [4]. We investigated the effect 
of these lipids when included in vesicles on the binding 
of biotin-DPPE liposomes to streptavidin. The results 
in Fig. 3 illustrate that inclusion of GhrI1, PEG,,, or 
PEGzm (5 mol%) caused a decrease in levels of lipid 
bound to streptavidin plates. As the length of the PEG 
moiety was increased from 550 to 2,000, levels of lipid 
bound to streptavidin plates decreased accordingly (41 
and 67%, respectively, of control biotin-DPPE li- 
posomes when 50 nmol ipid was added per well). Steric 
hindrance was less significant for biotin-DPPE li- 
posomes containing GM, (31% of control biotin-DPPE 
liposomes bound when 50 nmol lipid was added/well). 
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Fig. 3. Influence of stealth lipids on biotin-DPPE liposome binding to 
streptavidin. Liposomes (EPC 54.75-59.75 mol%; cholesterol 40 
mol%; biotin-DPPE 0.25 mol%) containing G,,, PEGSSO or PEG, 
(5 mol%) were prepared as described in section. Binding of liposome 
samples to streptavidin plates was determined as described in Fig. 1. 
3.2. In vivo behaviour of biotinylated liposomes 
Our interest is to use biotin-DPPE liposomes in tar- 
geting applications in vivo. We first examined the bio- 
distribution of EPC/cholesterol/G,, liposomes contain- 
ing biotin-DPPE in female mice bearing C26 tumours 
(Fig. 4). These liposome preparations had long circula- 
tion times in the blood. Up to 30--3X% of the injected 
dose was detected in the blood 3.5 h post-injection when 
liposomes were administered i.v. or i.p. After 24 h, lev- 
els of liposomes in tumours were high (15-30%). Tu- 
mour-associated radioactivity was due to liposome-en- 
capsulated “‘In-DTPA, as free “‘In-DTPA when in- 
jected i.v. was not detected in solid tumours 3.5 or 24 
h post-injection (Fig. 4). These results show that inclu- 
sion of biotin lipid derivatives in GM,-liposomes did not 
affect their ability to circulate for extended periods in 
the blood and extravasate to tumour sites. Increasing 
biotin-DPPE in vesicles up to 1 mol% did not affect this 
behaviour of liposomes in C26 tumour-bearing mice 
(data not shown). 
The ability of streptavidin to cross-link biotinylated 
targeting ligands with biotinylated liposomes within tu- 
mours will determine the success of diagnostic or thera- 
peutic applications based on pre-targeting protocols. 
With this aim in mind, we examined the accessibility of 
streptavidin to bind biotin-DPPE in liposomes at extra 
vascular sites within turnours. EPC/cholesterol/G,, li- 
posomes containing the fluorescent lipid marker 
cholesterol-BODIPY (0.5 mol%) and in some cases bio- 
tin-DPPE (0.25 mol%), were injected into tumour-bear- 
ing mice by the tail vein. Slices prepared from tumours 
24 h post-injection were probed for biotin binding reac- 
Fig. 4. In vivo behaviour of GM, liposomes containing biotin-DPPE 
in C26 tumour-bearing mice. Liposomes (EPC 62 mol%; cholesterol 
31 molb; GM, 6.2 molk; biotin-DPPE 0.25 mol%; 0.5pmol total lipid 
in 0.2 ml) containing trapped “‘In (15-20 PCi) were injected i.p. or 
i.v. into balblc female mice bearing tumours (0.7-0.8 cm in diameter). 
At 3.5 and 24 h liposome biodistribution in various organs was esti- 
mated as described in section 2. 
tivity with Texas red-labelled streptavidin. The fluores- 
cence emission spectra of tumour slices are shown in 
Fig. 5. An emission band at 515 nm due to BODIPY- 
derivatised cholesterol ester, was detected when tumour 
slices were prepared from mice injected with either bio- 
tinylated or non-biotinylated GM,-liposomes. A second 
signal at 600 um was detected when tumour slices pre- 
pared from mice injected with GM,-liposomes contain- 
ing biotin-DPPE, were probed with Texas red-labelled 
streptavidin. Under equivalent conditions, negligible 
levels of fluorescence were obtained at 600 nm when 
wNELENmH (ml) 
Fig. 5. Microspectrofluorimeter analysis of tumour sections. C26 tu- 
mour-bearing mice were injected with cholesterol-BODIPY liposomes 
containing Gh(, and in some cases biotin-DPPE. 24 h post-injection, 
tumours were isolated, thin sections were prepare and probed for 
reactivity with Texas red streptavidin. Fluorescent spectra were ob- 
tained from tumour sections isolated from mice injected with (dashed 
line) G,,-liposomes or (solid line) G,,-liposomes containing biotin- 
DPPE. 
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b&in-DPPE was uot included in the hposome formda- 
tion. 
The fluorescence patterns corresponding to the distri- 
bution of liposomes in tumours, before and after strep- 
tavidin labelling, are shown in Fig. 6. Natural fluores- 
cence due to tumour tissue was subtracted from images. 
Two distribution patterns of BODIPY-labelled li- 
posomes were present in the tumour sections: Fig. 6A 
shows diffuse fluorescence in extracellular spaces; Fig. 
6B shows groups of fluorescent granules localised near 
vessel-like structures. In the case of biotinylated li- 
posomes, the fluorescent signal due to Texas red strep- 
tavidin overlayed that attributed to cholesterol- 
BODIPY in liposomes (Fig. 63 and D). This was partic- 
ularly obvious in tumour regions displaying a clustered 
liposome distribution, and confirmed the interactian be- 
tween biotin residues on vesicle surfaces and strep- 
tavidin. Overall, tumour morphology suggests a distri- 
bution of liposomes in extracellular spaces and near 
blood vessels. 
4. DISCUSSION 
Targeted delivery of liposomes honing radionu- 
elides or ant&cancer agents to tumoum has significant 
diagnostic and therapeutic potential [l]. Our interests 
have concentrated on pre-targeting strategies which ex- 
ploit the high-afhuity binding of streptavidin to bioti- 
nylated molecules [5,6,9]. A possible strategy could be 
to sequentially label tumours with biotinylated anti- 
body, streptavidin and finally biotinylated liposomes. 
Accessibility of streptavidin to bind both biotinylated 
antibodies and biotinylated liposomes at tumour sites 
is essential for optimal tumour targeting. In this report 
we concentrated on optimising binding of biotin-DPPE 
liposomes to streptavidin. First we show that liposome 
composition can intluence the ability of bi~ti~y~t~ 
liposomes to bind streptavidin in vitro. Next we ad- 
dressed the in vivo properties of iiposomes containing 
both GM, and biotin-DPPE in tumour-bearing mice. It 
is shown that sterically stabilised liposome preparations 
containing biotin-DPPE remain intact in viva and ex- 
travasate at tumour sites. In addition we demonstrate 
that streptavidin has access to the biotin moiety in li- 
posomes within the extracellular spaces in solid tu- 
mours. This information supports the use of biotinyi- 
ated liposomes in indirect targeting protocols. 
The capacity of biotinyIated liposomes to bind ef& 
ciently to st~pt~vidin at tumour sites will be dictated 
by first the ability of liposomes to reach the tumour and 
secondly accessibility of streptavidin to biotin in li- 
posomes. Significant progress has been made in the de- 
sign of liposome formulations which avoid the reticu- 
loendothelial system, circulate for long times in the 
blood and extravasate at tumour sites [3,4]. Few studies 
have addressed how liposome components included in 
vesicles for optimal in vivo drug delivery applications 
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Fig. 6. Image analysis of tumour sections. Fluorescence patterns of 
tumour sections from animals treated with GM,-liposomes containing 
cholesterol-BODIPY and in some cases biotin-DPPE after staining 
with Texas red streptavidin are shown. Data were acquired at 51s nm 
fcorresponding to BODXPY emission) and 630 mn ~~~~pou~g to 
Texas red emission) and is corrected for natural fluorescence. 
affect the ability of liposomes to bind to target antigen. 
This study shows that inclusion of low amounts (0.25-i 
mol%) of biotin-derivatised lipid in EPClcholesterol 
liposomes is sufficient for optimal binding to strep 
tavidin. This corresponds to between 110-440 biotin 
molecules present in the outer monolayer for vesicles 
with a diameter of 100 mn. The ability of biotin-DPPE 
liposomes to bind to strepta~din is however dramati- 
cally influenced by inclusion of lipids possessing 
‘stealth properties in viva, For example, a 70% decrease 
in levels of lipid bound to str~~vi~-fated plates was 
detected for biotin-DPPE liposomes containing DPPE- 
PEG,, when compared to control biotin-DPPE li- 
posomes. This inhibitory effect was alleviated in part by 
reducing the length of PEG coupled to DSPE (PEG& 
or substitution with GM, (31% and 41% decrease ia % 
of lipid bound, respectively, when compared to control 
biotin-DPPE liposomes). 
To maxim&e binding of biotin-DPPE liposomes con- 
taining GM1 to s~p~vi~, it may be beneficial to in- 
troduce a spacer arm between the biotin moiety and the 
fiposome surface. Recently we observed that a 6 carbon 
spacer arm biotin derivative of DPPE (termed biotin-X- 
DPPE) alleviates steric hindrance attributed to G,, 
1151. However, inclusion of PEG,,-DSPE significantly 
inhibited binding of biotinylated liposomes to strep- 
tavidin-coated plates. Using a liposome-based aggluti- 
nation assay similar results were recently reported [17J. 
These findings suggest that the design of sterically sta- 
bilised liposome formulations for targeting applications 
in vivo may require a compromise between optimal cir- 
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culation times in the blood and optimal association of 
streptavidin with biotin-DPPE liposomes. 
Targeting of biotin-DPPE liposomes to streptavidin- 
coated tumour cells in vivo will depend first of all on 
their ability to access tumour sites. In this study we 
show that stealth liposomes containing 0.25 mol% bio- 
tin-DPPE have long circulation half-lives in the blood. 
At extended times substantial levels of biotin-DPPE li- 
posomes were detected in tumours (15-30%). Levels 
reported here are significantly higher than previous re- 
ports for GM,-liposomes (12% of injected dose/g tissue, 
[3]) or for DSPC/cholesterol iposomes containing bio- 
tin-X-DSPE (7% of injected dose/g tissue, [18]). The 
reason for this discrepancy is not clear. One possibility 
is that high grade GM, vs. commercially available prod- 
uct was used in these studies. Overall we conclude that 
inclusion of small amounts of biotin-DPPE in GM,- 
liposomes does not appear to affect vesicle stability or 
the stealth nature of the liposome preparation in vivo. 
In order to direct biotin-DPPE liposomes to strep- 
tavidin-coated antibodies within the tumour mass, bio- 
tin-DPPE should remain as an integral component of 
the lipid membrane. In addition biotin in liposomes 
must have access to streptavidin in extra-vascular 
spaces within the tumour. Previous studies have shown, 
using both aqueous and lipid markers, that GM,-con- 
taining liposomes have access to extra-vascular tumour 
spaces [3,4,19]. Using fluorescent microscopy we con- 
firm that biotin-DPPE liposomes containing G,, and 
the fluorescent liposome marker, cholesterol-BODIPY, 
localise within the vasculature of the tumour. We fur- 
ther demonstrate that the biotin moiety of DPPE in 
liposomes can be detected within tumours by specific 
interaction with Texas red-labelled streptavidin. Bioti- 
nylated liposomes may therefore bind to target cells 
when tumours are pre-labelled with biotinylated ligands 
and coated with streptavidin. 
In summary our work clearly supports the use of GM, 
liposomes containing biotin-DPPE in indirect targeting 
applications in vivo. This liposome system should be 
capable of binding to tumours coated with streptavidin- 
labelled biotinylated antibodies. At present the use of 
G,, liposomes containing biotin-DPPE in vivo would 
represent a compromise between optimum circulation 
half-lives in the blood and maximum capacity of strep- 
tavidin to bind biotin in liposomes. The development of 
novel biotinylated lipid derivatives which, when incor- 
porated into liposomes, confer stealth properties in vivo 
and in addition retain the ability to bind streptavidin 
efficiently, would increase the potential application of 
this approach to tumour targeting in vivo. 
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